XTL Biopharmaceuticals Ltd.

Contributing Author

Recent Articles by XTL Biopharmaceuticals Ltd.

Jun-30	XTL Completed the Acquisition of Psyga Bio Ltd. XTLB +15.68% XTLB -8.79% GlobeNewswire
May-22	XTL Announces Receipt of Staff Delist Determination from Nasdaq XTLB XTLB -5.18% GlobeNewswire
Apr-29	XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies XTLB +54.78% GlobeNewswire
Mar-20	XTL Biopharmaceuticals Announces ADS Ratio Change XTLB GlobeNewswire
Feb-27	XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing XTLB GlobeNewswire
Jan-29	XTL Update on Recent Developments XTLB -5.81% GlobeNewswire
Jan-23	XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency XTLB XTLB -10.08% GlobeNewswire
Jan-13	XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership XTLB +56.66% GlobeNewswire
Dec-24	XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency XTLB XTLB -5.74% GlobeNewswire